These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

508 related articles for article (PubMed ID: 35244503)

  • 1. Anticancer nanomedicines harnessing tumor microenvironmental components.
    Li Y; Chen Z; Gu L; Duan Z; Pan D; Xu Z; Gong Q; Li Y; Zhu H; Luo K
    Expert Opin Drug Deliv; 2022 Apr; 19(4):337-354. PubMed ID: 35244503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor Abnormality-Oriented Nanomedicine Design.
    Zhou Q; Xiang J; Qiu N; Wang Y; Piao Y; Shao S; Tang J; Zhou Z; Shen Y
    Chem Rev; 2023 Sep; 123(18):10920-10989. PubMed ID: 37713432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polysaccharide-Based Stimulus-Responsive Nanomedicines for Combination Cancer Immunotherapy.
    Li Q; Liu X; Yan C; Zhao B; Zhao Y; Yang L; Shi M; Yu H; Li X; Luo K
    Small; 2023 Jun; 19(23):e2206211. PubMed ID: 36890780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Remodeling tumor microenvironment with nanomedicines.
    Martin JD; Miyazaki T; Cabral H
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2021 Nov; 13(6):e1730. PubMed ID: 34124849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Responsive Role of Nanomedicine in the Tumor Microenvironment and Cancer Drug Resistance.
    Sa P; Sahoo SK; Dilnawaz F
    Curr Med Chem; 2023; 30(29):3335-3355. PubMed ID: 36154585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining Nanomedicine and Immunotherapy.
    Shi Y; Lammers T
    Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent Advances in Targeted Tumor Chemotherapy Based on Smart Nanomedicines.
    Qin SY; Zhang AQ; Zhang XZ
    Small; 2018 Nov; 14(45):e1802417. PubMed ID: 30247806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor microenvironment-responsive cell-penetrating peptides: Design principle and precision delivery.
    Wang C; Wang B; Zhang Q; Zhang S
    Colloids Surf B Biointerfaces; 2024 Oct; 242():114100. PubMed ID: 39024717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Boosting Nanomedicine Efficacy with Hyperbaric Oxygen Therapy.
    Wang X; Li S; Liu X; Wu X; Ye N; Yang X; Li Z
    Adv Exp Med Biol; 2021; 1295():77-95. PubMed ID: 33543456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functionalization of curcumin nanomedicines: a recent promising adaptation to maximize pharmacokinetic profile, specific cell internalization and anticancer efficacy against breast cancer.
    Zhang J; Sun J; Li C; Qiao H; Hussain Z
    J Nanobiotechnology; 2023 Mar; 21(1):106. PubMed ID: 36964547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances in dual- and multi-responsive nanomedicines for precision cancer therapy.
    Zhang Y; Li J; Pu K
    Biomaterials; 2022 Dec; 291():121906. PubMed ID: 36395660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Responsive and activable nanomedicines for remodeling the tumor microenvironment.
    Zhang Y; Han X; Nie G
    Nat Protoc; 2021 Jan; 16(1):405-430. PubMed ID: 33311713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strategies targeting tumor immune and stromal microenvironment and their clinical relevance.
    Hu M; Huang L
    Adv Drug Deliv Rev; 2022 Apr; 183():114137. PubMed ID: 35143893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanomedicines for advanced cancer treatments: Transitioning towards responsive systems.
    van Elk M; Murphy BP; Eufrásio-da-Silva T; O'Reilly DP; Vermonden T; Hennink WE; Duffy GP; Ruiz-Hernández E
    Int J Pharm; 2016 Dec; 515(1-2):132-164. PubMed ID: 27725268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-Targeted Nanomedicine for Immunotherapy.
    Cabral H; Kinoh H; Kataoka K
    Acc Chem Res; 2020 Dec; 53(12):2765-2776. PubMed ID: 33161717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Precise Subcellular Organelle Targeting for Boosting Endogenous-Stimuli-Mediated Tumor Therapy.
    Zhen W; An S; Wang S; Hu W; Li Y; Jiang X; Li J
    Adv Mater; 2021 Dec; 33(51):e2101572. PubMed ID: 34611949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomaterial-Based Responsive Nanomedicines for Targeting Solid Tumor Microenvironments.
    Avgoustakis K; Angelopoulou A
    Pharmaceutics; 2024 Jan; 16(2):. PubMed ID: 38399240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peptide ligand-modified nanomedicines for targeting cells at the tumor microenvironment.
    David A
    Adv Drug Deliv Rev; 2017 Sep; 119():120-142. PubMed ID: 28506743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stimuli-Responsive Nanomedicines for Overcoming Cancer Multidrug Resistance.
    Zhou L; Wang H; Li Y
    Theranostics; 2018; 8(4):1059-1074. PubMed ID: 29463999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What Went Wrong with Anticancer Nanomedicine Design and How to Make It Right.
    Sun D; Zhou S; Gao W
    ACS Nano; 2020 Oct; 14(10):12281-12290. PubMed ID: 33021091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.